InvestorsHub Logo
Followers 53
Posts 4314
Boards Moderated 0
Alias Born 02/28/2010

Re: None

Monday, 01/06/2014 1:06:22 PM

Monday, January 06, 2014 1:06:22 PM

Post# of 130513
Jason Napadano, the bio-tech analyst at Zacks, has a buy rating and a .20 price target on AMBS.

It wouldn't surprise me if several other analysts start covering the company within the next month with similar ratings and higher price targets.

Just saying!!! wink

Twitter: @AmarantusBio

p.s. Uplisting to the NASDAQ, fourth orphan indication for MANF, and expanding international exposure to Asia are just a few catalysts that will attract attention to $AMBS.